By analyzing ERBB2 mRNA expression data, researchers identified a group of HER2-negative patients with poor outcomes and potential markers of treatment resistance.

A follow-up of the ShortHER trial suggests tumor-infiltrating lymphocytes (TILs) can help identify patients who may benefit ...

The focus of the presentation will be on the subgroup of patients who have received 100mg bezuclastinib for at least 48 weeks to highlight the symptomatic benefits of long-term use.

Patients with ERBB2-positive breast cancer and CNS-only metastasis are at a high risk for CNS-related death but have longer overall survival than those with concomitant extracranial metastases.

A live webcast can be accessed on the Investors & Media page of Cogent’s website at https://investors.cogentbio.com/events. A replay will be available approximately two hours after the completion of ...

(HealthDay)—For patients with ERBB2-negative breast cancer, two years of treatment with celecoxib as adjuvant to conventional therapy yields no disease-free survival (DFS) benefits compared with ...

A global comparative study on real-world clinical and genomic differences in advanced biliary tract cancer. Extra-hepatic (ehCCA) and intra-hepatic cholangiocarcinomas (iCCA): A genomic landscape ...

Spatially resolved protein profiling in pancreatic adenosquamous carcinoma. Age, number of genomic alterations (GA) per tumor, and alteration frequency of select commonly altered genes based on TP53 ...